Thromboprophylaxis with apixaban and the risk of pulmonary embolism in patients undergoing knee replacement surgery

References

• Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, etal. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133(6 Suppl): 381S–453S.
   PubMed Web of Science ®Google Scholar
• Levine MN, Hirsh J, Gent M, Turpie AG, Leclerc J, Powers PJ, etal. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med. 1991; 114(7): 545–51.
   PubMed Web of Science ®Google Scholar
• Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, etal. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329(19): 1370–6.
   Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 204S–33S.
   PubMed Web of Science ®Google Scholar
• Dahl OE, Pleil AM. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement. J Thromb Haemost. 2003; 1(5): 896–906.
   Web of Science ®Google Scholar
• Bauer KA. Recent progress in anticoagulant therapy: Oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost. 2011; 9(Suppl 1): 12–19.
   Web of Science ®Google Scholar
• Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, etal. Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008; 6(5): 820–9.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361(6): 594–604.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, etal. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363(26): 2487–98.
   PubMed Web of Science ®Google Scholar
• Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, etal. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial. Lancet. 2010; 375(9717): 807–15.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, etal. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009; 339: b2700.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez L-M, Wright RT, etal. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: Pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012; 94(2): 257–64.
   PubMedGoogle Scholar
• Shuster JJ. Review: Cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors. Res Synth Methods. 2011; 2(2): 126–30.
   Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, etal. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials. 1996; 17(1): 1–12.
   PubMedGoogle Scholar
• Li X-M, Sun S-G, Zhang W-D. Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: A meta-analysis of randomized controlled trials. Chin Med J (Engl). 2012; 125(13): 2339–45.
   Web of Science ®Google Scholar
• Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5(12): 2368–75.
   PubMed Web of Science ®Google Scholar